Effect of paliperidone palmitate 3-month formulation on goal attainment and disability after 52 weeks’ treatment in patients with clinically stable schizophrenia

Vista sencilla de ítem
dc.contributor.authorLambert, Martin
dc.contributor.authorSánchez Gómez, Pedro Manuel
dc.contributor.authorBergmans, Paul
dc.contributor.authorGopal, Srihari
dc.contributor.authorMathews, Maju
dc.contributor.authorWooller, Annette
dc.contributor.authorPungor, Katalin
dc.date.accessioned2025-10-10T06:57:46Z
dc.date.available2025-10-10T06:57:46Z
dc.date.issued2020-12-23
dc.date.updated2025-10-10T06:57:46Z
dc.description.abstractPurpose: This pragmatic clinical study aimed to assess goal attainment among patients with schizophrenia treated with paliperidone palmitate 3-monthly (PP3M) and its relation to their level of disability, and whether patients achieved symptomatic remission at the study endpoint. Patients and Methods: Goal attainment was assessed as a secondary endpoint using Goal Attainment Scaling (GAS) within a 52-week, prospective, single-arm, non-randomized, open-label, international, multicenter study evaluating the impact of transitioning stable patients with schizophrenia from paliperidone palmitate 1-monthly (PP1M) to PP3M. Additional exploratory analyses were performed to investigate the relationship between disability and functioning as measured by the World Health Organization Disability Assessment Schedule (WHODAS), Version 2.0, symptomatic remission, and goal attainment. Results: Overall, 305 patients were enrolled, of whom 281 (92.1%) provided GAS data at baseline. Of these, 160 achieved symptomatic remission at the last observation carried forward (LOCF) endpoint. The most common category of goals was “self” related, of which work-related was most frequent. Two-thirds of patients (67.7%) achieved at least one goal at the LOCF endpoint. Goal achievement was positively associated with lower baseline symptoms and symptomatic remission at LOCF endpoint, and with lower WHODAS scores at baseline and LOCF endpoint and greater WHODAS score improve-ments from baseline. Age, duration of disease, and duration of PP1M treatment before the switch did not impact goal setting and goal attainment. The proportion of patients with remunerated work status increased by 11.3% at LOCF endpoint. Conclusion: The results of this secondary endpoint analysis indicate that continued treatment of patients with schizophrenia with PP3M following stabilization with PP1M may facilitate attainment of patients’ personal goals and reduce disability, especially, but not exclusively, in patients with symptomatic remission achieved at LOCF.en
dc.description.sponsorshipThis research was sponsored by Janssen, which has marketing authorization for PP1M and PP3M in Europeen
dc.identifier.citationLambert, M., Sanchez, P., Bergmans, P., Gopal, S., Mathews, M., Wooller, A., & Pungor, K. (2020). Effect of paliperidone palmitate 3-month formulation on goal attainment and disability after 52 weeks’ treatment in patients with clinically stable schizophrenia. Neuropsychiatric Disease and Treatment, 16, 3197-3208. https://doi.org/10.2147/NDT.S286654
dc.identifier.doi10.2147/NDT.S286654
dc.identifier.eissn1178-2021
dc.identifier.urihttps://hdl.handle.net/20.500.14454/3918
dc.language.isoeng
dc.publisherDove Medical Press Ltd
dc.rights© 2020 Lambert et al.
dc.subject.otherGAS
dc.subject.otherGoal attainment
dc.subject.otherPaliperidone palmitate 1-monthly formulation
dc.subject.otherPaliperidone palmitate 3-monthly formulation
dc.subject.otherSchizophrenia
dc.subject.otherWHODAS
dc.titleEffect of paliperidone palmitate 3-month formulation on goal attainment and disability after 52 weeks’ treatment in patients with clinically stable schizophreniaen
dc.typejournal article
dcterms.accessRightsopen access
oaire.citation.endPage3208
oaire.citation.startPage3197
oaire.citation.titleNeuropsychiatric Disease and Treatment
oaire.citation.volume16
oaire.licenseConditionhttps://creativecommons.org/licenses/by-nc/3.0/
oaire.versionVoR
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
lambert_effect_2020.pdf
Tamaño:
499.7 KB
Formato:
Adobe Portable Document Format
Descargar
Colecciones
Artículos